Hereditary angioedema is a disorder that results in frequent attacks of pain and inflammation accompanied with the swelling of legs, intestinal tract, arms, face and airway tract. There are three types of hereditary angioedema, types I, II and III which are distinguished by the underlying causes and the levels of blood protein called C1 inhibitors. Phenotypic expression in hereditary angioedema varies widely even among family members, the frequency and severity of attacks are unpredictable giving an expression that similar symptoms arises in all types. Type III was initially thought to be prevalent only in women but incidences have occurred in males in the same affected families.

For the purpose of this study, the global hereditary angioedema market is studied in terms of drug classes, pipeline drugs and geography. The drug classes studied in the report include C1 esterase inhibitors (Berinert, Haegarda, Cinryze and Ruconest), kallikrein inhibitors (Kalbitor), selective bradykinin B2 receptor antagonist (Firazyr) and others. The current pipeline drugs for this market include Phase III drug DX-2930 and phase II drug BCX-7353. 

The geographic segmentation of the global hereditary angioedema market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 

Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global hereditary angioedema market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global hereditary angioedema market. The key players profiled in this report are BioCryst Pharmaceuticals, Inc., Cipla, Inc., CSL Behring Ltd., Ionis Pharmaceuticals, Inc., iBio, Inc., Merck & Co., Inc., Pharming Group NV, Sanofi N.V., Shire plc, and Teva Pharmaceutical Industries Ltd.

Drug class Analysis

The hereditary angioedema market is driven by factors such as increasing expenditure in pharmaceutical and biotechnology R&D focusing on genetic rare diseases, rising public awareness and alliances between pharmaceutical giants and research institutes. In addition, increasing number of diagnostic centers and growing physician awareness regarding disease etiology will propel the market penetration of hereditary angioedema drugs. In 2016, C1 esterase inhibitors segment held the largest market share chiefly due to factors such as recent FDA approval of Berinert and Haegarda. Technological advancement in the drug delivery for e.g. Haegarda is the only medication available as a subcutaneous treatment option for hereditary angioedema. Kallikrien inhibitors will be the fastest growing segment throughout the forecast period 2017-2025. Factors contributing to the growth of this segment are increasing incidences in patients with angioedema anaphylactic shock and promising product pipeline consisting of selective kallikrien inhibitors and plasma kallikrien inhibitors resulting in immediate relief due to faster onset of action. The major players in hereditary angioedema market are BioCryst Pharmaceuticals, Inc., Cipla, Inc., CSL Behring Ltd., Ionis Pharmaceuticals, Inc., iBio, Inc., Merck & Co., Inc., Pharming Group NV, Sanofi N.V., Shire plc, Teva Pharmaceutical Industries Ltd.

North America was observed to be the largest market for hereditary angioedema in the base year 2021. According to the US Hereditary Angioedema Association, in 2016, about 3,904 people suffered with hereditary angioedema. The dominance of North America is mainly attributed to the presence of key drivers such as rising prevalence of hereditary angioedema, presence of pharmaceutical giants such as BioCryst Pharmaceuticals, Inc., CSL Behring and existence of developed research and healthcare institutions. The market growth in Europe is mainly attributed to the rising prevalence of genetic rare diseases, increasing demand for novel drugs for the treatment of hereditary angioedema and affordable reimbursement scenario for the treatment of genetic rare diseases. Asia Pacific was observed as the fastest growing regional segment throughout the forecast period 2023-2030. Factors that are anticipated to propel the market growth are the increasing disposable income and supportive regulatory environment for hereditary angioedema products. Moreover, factors such as developing health infrastructure, expansion by pharmaceutical giants in the untapped market of remote areas with unmet medical needs are going to fuel the rapid growth of hereditary angioedema market in Latin America, and Middle East and Africa in the near future.   

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Hereditary Angioedema market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Hereditary Angioedema market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Hereditary Angioedema market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Hereditary Angioedema market?
• Which is the largest regional market for Hereditary Angioedema market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Hereditary Angioedema market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Hereditary Angioedema market worldwide?